The FDA (Food and Drug Administration) Drug Approval Process Online Training Course (June 11-12, 2025): Essential Strategies for INDs, NDAs, ANDAs, and 505(b)(2) Applications
06 févr. 2025 12h43 HE
|
Research and Markets
Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
FDA (Food and Drug Administration) Drug Approval Process Training Course: Practical Insights into FDA Requirements and Up to Date Developments (ONLINE EVENT: February 24-25, 2025)
30 janv. 2025 07h54 HE
|
Research and Markets
Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" has been added to ResearchAndMarkets.com's offering. The US is the...
FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND)
21 nov. 2024 06h08 HE
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
Drug Discovery and Early Development Outsourcing Services - Growth Opportunities in De Novo Drug Design and Disease Modeling with Generative AI
02 avr. 2024 07h49 HE
|
Research and Markets
Dublin, April 02, 2024 (GLOBE NEWSWIRE) -- The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering. The...
The FDA (Food and Drug Administration) Drug Approval Process, 2 Day Virtual Training Course
22 janv. 2024 11h43 HE
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" has been added to ResearchAndMarkets.com's offering. The US is the...
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
02 janv. 2024 08h35 HE
|
Pasithea
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.
CP101 for Chronic Hepatitis B Pipeline Report 2023: Emerging Drug Insights and Market Forecasts, 2019-2032 - Focus on 7 Major Markets
23 nov. 2023 11h33 HE
|
Research and Markets
Dublin, Nov. 23, 2023 (GLOBE NEWSWIRE) -- The "CP101 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This "CP101 Emerging Drug Insight...
Mastering the FDA Drug Approval Process: Strategies for Success in the US Pharmaceutical Market (February 6-7, 2024)
02 nov. 2023 07h28 HE
|
Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
18 sept. 2023 16h16 HE
|
Sixty Degrees Pharmaceuticals
Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use...
Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
29 juin 2023 08h29 HE
|
Pasithea
PALO ALTO, Calif. and MIAMI, June 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...